PDE4 Inhibitors: Bridging Molecular Insights With Clinical Impact
1. 请及时下载文件确认是否正确, 系统将在 2026-04-30 17:30:23 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
NT Issa, S Obagi, G Damiani…
Journal of drugs in …, 2025
pubmed.ncbi.nlm.nih.gov
Phosphodiesterase-4 (PDE4) inhibitors are reshaping the treatment landscape for chronic inflammatory skin diseases by offering effective, non-steroidal options for conditions like psoriasis, atopic dermatitis, and seborrheic dermatitis. This perspective translates recent structural biology and biochemical findings into clinically meaningful guidance. Among available agents, roflumilast stands out for its high potency and selectivity, with a half-maximal inhibitory concentration of 0.7 nM compared to 140 nM for apremilast (200-fold …
